Unichem LaboratoriesNSE:UNICHEMLAB -0.13%65 EBITDA Margin % is 10.22% as of Mar. 2026, which is 178% above its 10-year median of 3.67. GuruFocus rates NSE:UNICHEMLAB with a GF Score™ of 65/100 and a GF Value™ of ₹686.18 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Unichem Laboratories ranks better than 68.8% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Unichem Laboratories EBITDA Margin % Related Terms
Unichem Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Unichem Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Unichem Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unichem Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unichem Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Unichem Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unichem Laboratories (NSE:UNICHEMLAB) has a EBITDA Margin % of 10.22% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Unichem Laboratories and its competitors. This is 178% above median its historical median of 3.67. According to the industry distribution chart, Unichem Laboratories ranks #298 out of 955 companies in the Drug Manufacturers industry, placing it in the top 31.2%.
Is Unichem Laboratories' EBITDA Margin % too high?
Unichem Laboratories' current EBITDA Margin % of 10.22% is 178% above median its 10-year median of 3.67. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Unichem Laboratories' value of 10.22% is 17.5% below this industry median. Based on the distribution chart, Unichem Laboratories ranks #298 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Unichem Laboratories has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Unichem Laboratories' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Unichem Laboratories ranks #298 out of 955 companies for EBITDA Margin %. This puts Unichem Laboratories in the upper half of its industry. The industry median EBITDA Margin % is 12.39. Unichem Laboratories' value of 10.22% is 17.5% below this benchmark. While the company's 10-year median is 3.67 vs. the industry median of 12.39, Unichem Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unichem Laboratories's current EBITDA Margin % of 10.22% is 17.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Unichem Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unichem Laboratories's current EBITDA Margin % is 10.22%, which is 178% above median its own 10-year median of 3.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unichem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Unichem Laboratories (NSE:UNICHEMLAB) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹686.18, compared to a current price of ₹433.00 — trading 36.9% below its estimated fair value. The current EBITDA Margin % is 10.22%, which is 178% above median its 10-year median of 3.67 and 17.5% below the Drug Manufacturers industry median of 12.39. Unichem Laboratories' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Unichem Laboratories (NSE:UNICHEMLAB), the current EBITDA Margin % is 10.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unichem Laboratories (NSE:UNICHEMLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Unichem Laboratories stock appears to be undervalued.
The current stock price of ₹433.00 is trading 36.9% below its estimated GF Value™ of ₹686.18.
GuruFocus considers Unichem Laboratories to be Significantly Undervalued.
Key valuation signals for NSE:UNICHEMLAB:
EBITDA Margin %: 10.22% (178% above median its 10-year median of 3.67)
GF Value™: ₹686.18 vs. price of ₹433.00 (36.9% below fair value)
Industry Position: 17.5% below the Drug Manufacturers median (#298 of 955)
No single metric tells the full story. See the NSE:UNICHEMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unichem Laboratories Ltd is an India based pharmaceutical company. It manufactures a range of Active Pharmaceutical Ingredients (APIs). The company's products are offered in the areas of gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. Some of its products include Apixaban, Brimonidine Tartrate, Finofibrate, Glipizide, Piroxicam and others. The company has a market presence with sales in India and outside India, and the majority of the revenue derived from India. Its product categories comprises Formulations and Bulk Drugs and Chemicals.
65GF Score
Get the complete analysis for NSE:UNICHEMLAB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:UNICHEMLAB has been successfully added to your 
